Rituximab Benefit in MCL

This ongoing phase II trial examined the efficacy of rituximab when added to ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL). Findings were presented at the 2014 American Society of Hematology annual meeting. Of the 50 patients with MCL, 45 were evaluable. The overall response rate (ORR) was 87% (n = 39) with complete response in 17 patients (38%) and partial response in 22 patients (49%). Among those with Ki-67 <50%, the ORR was 100%; in those with Ki-67 ≥50%, the ORR was 50%.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.